Showing 1431-1440 of 1614 results for "".
- Lumenis Named “Best Overall Medical Device Company” in 2021 MedTech Breakthrough Awardshttps://modernod.com/news/lumenis-named-best-overall-medical-device-company-in-2021-medtech-breakthrough-awards/2479201/Lumenis announced that it has been selected as the “Best Overall Medical Device Company” in the MedTech Breakthrough Awards. MedTech Breakthrough is an independent market intelligence organization that honors excellence and recognizes the top companies, technologies and products in the global he
- Gyroscope Therapeutics Postpones Initial Public Offeringhttps://modernod.com/news/gyroscope-therapeutics-postpones-initial-public-offering/2479176/Gyroscope Therapeutics announced it has postponed plans for its initial public offering. “In light of market conditions, we have decided to postpone our planned initial public offering,” Khurem Farooq, Chief Executive Officer, said in a company news release. “Based on the
- Rayner Launches the Plus1 EMV Campaign on Monovision Educationhttps://modernod.com/news/rayner-launches-the-plus1-emv-campaign-on-monovision-education/2479168/With the global rollout of the RayOne EMV IOL to markets around the world, Rayner announced a new campaign intended to extoll the benefits of monovision (including “Mini”, “Micro”, or “Blended”). “The Plus1 EMV: A global discussion on Enhanced Monovision campaign”
- Pfizer, BioNTech Seek EU Nod to Allow COVID-19 Vaccine Use in Younger Teenshttps://modernod.com/news/pfizer-biontech-seek-eu-nod-to-allow-covid-19-vaccine-use-in-younger-teens/2479158/Pfizer and BioNTech said they have asked the European Medicines Agency (EMA) to extend the conditional marketing authorization for their COVID-19 vaccine Comirnaty to adolescents 12 to 15 years of age. The companies recently made a similar request to the FDA for the vaccine, which is already auth
- Heidelberg Engineering and RetInSight to Offer AI-Based OCT Fluid Quantification Solutionhttps://modernod.com/news/heidelberg-engineering-and-retinsight-to-offer-ai-based-oct-fluid-quantification-solution/2479136/Heidelberg Engineering and RetInSight announced they intend to interface the RetInSight AI-based fluid monitor application with the Heidelberg Engineering product portfolio, using cloud exchange and application marketplace technologies. RetInSight utilizes a novel, proprietary algorithm, t
- Alcon Launches Systane Hydration Multi-Dose Preservative-Free Lubricant Eye Drops in the U.S.https://modernod.com/news/alcon-launches-systane-hydration-multi-dose-preservative-free-lubricant-eye-drops-in-the-u-s/2479131/Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of the newest addition to its innovative portfolio of dry eye products – Systane® Hydration Multi-Dose Preservative-Free (MDPF) Lubricant Eye Dro
- Ocumension Therapeutics Licenses Alimera’s Fluocinolone Acetonide Intravitreal Implant in Chinahttps://modernod.com/news/ocumension-therapeutics-licenses-alimeras-fluocinolone-acetonide-intravitreal-implant-in-china/2479075/Alimera Sciences announced that Ocumension Therapeutics has acquired an exclusive license agreement for Alimera’s 0.19mg fluocinolone acetonide intravitreal implant, which Alimera markets elsewhere under the trademark Iluvien. The license grants Ocumension the rights to develop and commercialize
- LumiThera Announces Topline Data in the European Multicenter LIGHTSITE II Study to Treat Dry AMDhttps://modernod.com/news/lumithera-announces-topline-data-in-the-european-multicenter-lightsite-ii-study-to-treat-dry-amd/2479059/LumiThera announced positive findings in its LIGHTSITE II multicenter clinical trial in dry age-related macular degeneration (AMD) patients. The prospective, double-masked, randomized, multicenter, European Union post-marketing clinical trial, titled LIGHTSITE II, was conducted in eight re
- Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucomahttps://modernod.com/news/aerie-pharmaceuticals-announces-publication-of-peer-reviewed-paper-evaluating-the-treatment-effect-of-netarsudil-on-outflow-function-in-steroid-induced-glaucoma/2479030/Aerie Pharmaceuticals announced the publication of a peer-reviewed paper in eLife entitled, “Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis.” This paper evaluates the treatment effect of netarsudil, marketed as Rhopressa (ne
- Pfizer, BioNTech Initiate Study of COVID-19 Vaccine in Children Under 12https://modernod.com/news/pfizer-biontech-initiate-study-of-covid-19-vaccine-in-children-under-12/2479017/Pfizer and BioNTech said Thursday that they have started testing their COVID-19 vaccine BNT162b2 in children ages 6 months to 11 years old, with initial results expected in the second half of the year. The mRNA-based vaccine is currently authorized for people 16 years and older in multiple market